Physician profile
Todd Hutton
NPI 1760535959
$40,574.28
in general payments reported to CMS, 2019-2025
22 companies · $10K in 2025
The $10K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $3,073 · 2021: $7,471 · 2022: $4,924 · 2023: $8,981 · 2024: $4,317 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $4,324 · Travel and Lodging: $479 · Consulting Fee: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,413.75 |
| Food and Beverage | $4,324.37 |
| Travel and Lodging | $479.00 |
| Consulting Fee | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $32,954.39 | 2019-2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $1,315.28 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,273.93 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $787.90 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $664.33 | 2019-2025 | Trintellix |
| Lundbeck LLC | $601.99 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $560.04 | 2019-2025 | Hetlioz, Fanapt |
| Corium, LLC | $480.84 | 2023-2025 | Azstarys |
| Bausch Health US, LLC | $407.47 | 2019-2023 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $375.32 | 2019-2022 | |
| Allergan, INC. | $291.96 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.42 | 2022-2025 | Caplyta |
| Alkermes, INC. | $210.70 | 2019-2023 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $104.08 | 2022-2025 | Auvelity |
| Eisai INC. | $92.84 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.91 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $37.31 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $23.27 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $20.03 | 2023 | Lokelma |
| Livanova USA, INC. | $18.79 | 2021 | |
| Harmony Biosciences LLC | $17.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Hutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.